Compare FA & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FA | AMLX |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2021 | 2021 |
| Metric | FA | AMLX |
|---|---|---|
| Price | $12.63 | $16.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $15.67 | ★ $21.56 |
| AVG Volume (30 Days) | 891.0K | ★ 1.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.97 | 65.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,574,389,000.00 | $380,786,000.00 |
| Revenue This Year | $8.42 | N/A |
| Revenue Next Year | $7.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 83.02 | ★ 1612.94 |
| 52 Week Low | $8.82 | $4.41 |
| 52 Week High | $19.01 | $18.61 |
| Indicator | FA | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 55.22 | 53.32 |
| Support Level | $12.10 | $12.29 |
| Resistance Level | $12.78 | $17.22 |
| Average True Range (ATR) | 0.53 | 0.82 |
| MACD | -0.00 | -0.20 |
| Stochastic Oscillator | 44.44 | 35.46 |
First Advantage Corp is a provider of software and data in the Human Resources technology industry. The company provides end-to-end identity solutions, criminal background screening, credential verifications, drug and health screening, and continuous risk monitoring. It combines AI-powered proprietary technology platforms with proprietary data, primary source data, and third-party data. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. The company generates maximum revenue from the Sterling segment, which provides similar services as compared to First Advantage's Americas and International segments on a global basis. Geographically, the company generates the majority of its revenue from the United States.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.